Literaturdatenbank
Literaturdatenbank |
|
 |
|
Frew, S. E., Sammut, S. M., Shore, A. F., Ramjist, J. K., Al-Bader, S., & Rezaie, R., et al. (2008). Chinese health biotech and the billion-patient market: Chinese government support and „sea turtles“ are spurring the sector, but investors lack exits. Nature Biotechnology, 26, 37–53.
Added by: Sarina Wunderlich (28 Apr 2009 14:28:30 UTC) Last edited by: Sarina Wunderlich (28 Apr 2009 14:31:10 UTC) |
| Resource type: Journal Article DOI: 10.1038/nbt0108-37 BibTeX citation key: Frew2008a View all bibliographic details  |
Categories: General Keywords: Schildkröten = turtles + tortoises Creators: Al-Bader, Daar, Frew, Ramjist, Rezaie, Sammut, Shore, Singer Collection: Nature Biotechnology |
Views: 3/540
Views index: 9% Popularity index: 2.25% |
| Abstract |
|
As home to nearly 20% of the world's population, China bears the world's largest health burden. Yet despite the country's incredible economic growth (gross domestic product (GDP) grew by >10% in 2006), the country ranks only 81st out of 177 countries on the Human Development Index, a measure of progress in healthcare. Exacerbating this is China's unequal distribution of wealth, with development in the inland provinces lagging far behind the coastal regions, and cities facing unprecedented growth as workers migrate from rural areas in search of jobs, resulting in considerable inequities. This rapid transformation presents the Chinese government with a significant challenge in delivering equitable healthcare to its citizens, particularly the 10% living in poverty.
Added by: Sarina Wunderlich Last edited by: Sarina Wunderlich |
| Notes |
|
WIF
Added by: Sarina Wunderlich Last edited by: Sarina Wunderlich |